141 results
Page 4 of 8
8-K
EX-99.1
4qwflfc1 yco2iex3
1 Jun 21
Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder
7:09am
8-K
EX-99.1
purjq1f2wy11g
25 Mar 21
Regulation FD Disclosure
12:00am
8-K
EX-99.1
jbpki580 ebhju6irtt
11 Feb 21
Results of Operations and Financial Condition
7:05am
8-K
EX-99.1
wusm5i
11 Jan 21
Regulation FD Disclosure
7:00am
8-K
EX-99.1
9leh 3qs8fx7bt7
17 Nov 20
Alkermes Receives FDA Complete Response Letter Related to ALKS 3831 Manufacturing Records Review
7:15am
8-K
EX-99.2
tl9wcpyie4hxoq 5ld
29 Oct 20
Alkermes plc Reports Third Quarter 2020 Financial Results and Raises 2020 Financial Expectations
7:06am
8-K
EX-99.1
h5wufcauodblzq9q13v
29 Oct 20
Alkermes plc Reports Third Quarter 2020 Financial Results and Raises 2020 Financial Expectations
7:06am
8-K
EX-99.1
hb19sg80juijfpzo0fpg
9 Oct 20
FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder
5:20pm
8-K
EX-99.1
q7y4moqmw5y13l8kugq
29 Jul 20
Alkermes plc Reports Second Quarter 2020 Financial Results and Issues 2020 Financial Expectations
7:08am
8-K
EX-99.2
l1z9qx8c0luiah7
29 Jul 20
Alkermes plc Reports Second Quarter 2020 Financial Results and Issues 2020 Financial Expectations
7:08am